• Nuo Therapeutics amended and restated its loan and security agreement with five lenders on May 29, lifting total commitments to USD 2 million.
• USD 1 million funded in January, USD 675,000 funded May 29, USD 325,000 available Sept. 30 subject to conditions.
• Notes carry 12% annual interest, payable in Interest Warrants rather than cash; maturity remains Dec. 31, 2028.
• Debt is secured by a lien on all company assets, including intellectual property; proceeds earmarked for working capital.
• Deal includes warrants at USD 1.5 per share; mandatory prepayment triggered by a USD 5 million equity raise or a change in control.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-019199), on June 03, 2026, and is solely responsible for the information contained therein.